Real Clinics. Real Patients. Real Oncology.

Home /

Therapeutic Approaches

Therapeutic Approaches

Home /

Therapeutic Approaches

Home /

News / Therapeutic Approaches

FDA Approvals

Quadruplet Regimen Approved for Transplant-Ineligible NDMM Patients

FDA approves D-VRd quadruplet for transplant-ineligible newly diagnosed multiple myeloma based on CEPHEUS trial PFS and MRD negativity gains.

April 16, 2026

Therapeutic Approaches

FDA Approvals

Quadruplet Regimen Approved for Transplant-Ineligible NDMM Patients

April 16, 2026

FDA Approvals

Reconsidering Venetoclax Dosing With Azole Antifungals

Grant Drew, PharmD; Kiwon Park, PharmD; et al.

April 16, 2026

Clinical Trials

North American Enrollment in Clinical Trials

Ming-Hei Tai, PharmD, BCOP

April 15, 2026

FDA Approvals

Quadruplet Regimen Approved for Transplant-Ineligible NDMM Patients

April 16, 2026

FDA Approvals

Reconsidering Venetoclax Dosing With Azole Antifungals

Grant Drew, PharmD; Kiwon Park, PharmD; et al.

April 16, 2026

Clinical Trials

North American Enrollment in Clinical Trials

Ming-Hei Tai, PharmD, BCOP

April 15, 2026

News & Insights

FDA Approvals

Quadruplet Regimen Approved for Transplant-Ineligible NDMM Patients

April 16, 2026

FDA Approvals

Reconsidering Venetoclax Dosing With Azole Antifungals

Grant Drew, PharmD; Kiwon Park, PharmD; et al.

April 16, 2026

Clinical Trials

North American Enrollment in Clinical Trials

Ming-Hei Tai, PharmD, BCOP

April 15, 2026

Podcasts

No results were found